Baird served as a co-manager on this offering
AboutTESARO, Inc. (“TESARO” or the “Company”) (NASDAQ: TSRO) recently completed a follow-on offering of 3,755,000 shares of common stock at a price of $51.00 per share, generating gross proceeds of approximately $192 million. The Company intends to use the net proceeds to fund potential commercialization activities for oral rolapitant, clinical trials for IV rolapitant, niraparib and other product candidates, to carry out its immuno-oncology platform strategy, and for working capital and general corporate purposes.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and is currently developing three clinical-stage product candidates, rolapitant (in registration), niraparib (phase 3) and TSR-011 (phase ½). TESARO is headquartered in Waltham, Massachusetts.
For additional information about this transaction, please contact:
- March 2015
- TESARO, Inc.
- Target Location
- North America